Cheyne–Stokes respiration.

Validation of ApneaLink as screening device for sleep-disordered breathing (SDB).

The ApneaLink device provides you with a cost-effective, easy-to-use method of diagnosing or screening patients for obstructive sleep apnea (OSA) in the home. The device reports apneas, hypopneas, flow limitation, estimated blood oxygen saturation and the probability of Cheyne-Stokes respiration (CSR) breathing patterns within the recording.

Sleep-disordered breathing (SDB) is recognized as a serious health problem that impacts approximately 43 million US adults. More than 80% remain undiagnosed, and many barriers prevent patients from getting access to therapy.

Now, the detection of this chronically debilitating condition has been made easier with the ApneaLink Plus, a fax-size portable monitoring device, the latest addition to the ApneaLink family of diagnostic products and accessories. The ApneaLink devices provide you with a cost-effective, easy-to-use method of diagnosing or screening patients for obstructive sleep apnea (OSA) in the home. The device reports apneas, hypopneas, flow limitation, estimated blood oxygen saturation and the probability of Cheyne-Stokes respiration (CSR) breathing patterns within the recording.

The study demonstrated that the screening classifier was able to detect CSR patterns within the recording.

3 Values reported as AHI for MicroMESAM (ApneaLink) are actually RDI values per hour (continued).

Validations of MicroMESAM as screening devices for sleep-disordered breathing.

The study demonstrated that the screening classifier was able to detect CSR patterns within the recording.

Validations of ApneaLink as screening devices for Cheyne-Stokes respiration.

The study demonstrated that the screening classifier was able to detect CSR patterns within the recording.

Validations of ApneaLink as screening devices forCheyne-Stokesrespiration.

The study demonstrated that the screening classifier was able to detect CSR patterns within the recording.

Validations of ApneaLink as screening devices for Cheyne-Stokes respiration.

The study demonstrated that the screening classifier was able to detect CSR patterns within the recording.

Validations of ApneaLink and ApneaLink Plus results was good at any time. The differentiation between the apnea event types showed a good correlation and reliably through the entire study. The correlation between PSG results and manually scored apneas was 90% or higher. The correlation between PSG results and ApneaLink Plus results was good at any time. The differentiation between the apnea event types showed a good correlation and reliably through the entire study. The correlation between PSG results and manually scored apneas was 90% or higher. The correlation between PSG results and ApneaLink Plus results was good at any time. The differentiation between the apnea event types showed a good correlation and reliably through the entire study. The correlation between PSG results and manually scored apneas was 90% or higher. The correlation between PSG results and ApneaLink Plus results was good at any time. The differentiation between the apnea event types showed a good correlation and reliably through the entire study. The correlation between PSG results and manually scored apneas was 90% or higher. The correlation between PSG results and ApneaLink Plus results was good at any time. The differentiation between the apnea event types showed a good correlation and reliably through the entire study. The correlation between PSG results and manually scored apneas was 90% or higher.
ResMed’s ApneaLink devices are the easy choice in OSA diagnosis

The ApneaLink™ improves patient care by providing easy access to treatment while helping you grow your sleep apnea business.

ApneaLink features:
- Automatic analysis: Detects apnea, hypopnea index (AHI), hypopnea index (HI), flow limitation, and oxygen desaturation index (ODI).
- Individual results meet AASM and CMS definitions for hypopneas scoring guidelines.
- Cheyne–Stokes probability detection introduces our unique algorithm to identify Cheyne–Stokes breathing patterns.
- Results can be secured immediately for more detailed patient data.
- Your business logo can be printed when programming the device to refer patients for further in-lab diagnosis.
- Results can be sent to referral physicians or other relevant parties.
- Patient instructions can be printed when programming the device.

ApneaLink Plus additional features:
- Six measurements of oxygen saturation including ≤ 89 and ≤ 88%.
- Differentiation of apneas, hypopneas, and central apneas.
- Configuration analysis parameters allow for the adjustment of obstructive and central apneas thresholds.
- Five measurements of oxygen saturation including ≤ 89 and ≤ 88%.

ApneaLink Plus additional features:
- Six measurements of oxygen saturation including ≤ 89 and ≤ 88%.
- Differentiation of apneas, hypopneas, and central apneas.
- Configuration analysis parameters allow for the adjustment of obstructive and central apneas thresholds.
- Five measurements of oxygen saturation including ≤ 89 and ≤ 88%.

ApneaLink Plus additional features:
- Six measurements of oxygen saturation including ≤ 89 and ≤ 88%.
- Differentiation of apneas, hypopneas, and central apneas.
- Configuration analysis parameters allow for the adjustment of obstructive and central apneas thresholds.
- Five measurements of oxygen saturation including ≤ 89 and ≤ 88%.

ApneaLink Plus additional features:
- Six measurements of oxygen saturation including ≤ 89 and ≤ 88%.
- Differentiation of apneas, hypopneas, and central apneas.
- Configuration analysis parameters allow for the adjustment of obstructive and central apneas thresholds.
- Five measurements of oxygen saturation including ≤ 89 and ≤ 88%.

ApneaLink Plus additional features:
- Six measurements of oxygen saturation including ≤ 89 and ≤ 88%.
- Differentiation of apneas, hypopneas, and central apneas.
- Configuration analysis parameters allow for the adjustment of obstructive and central apneas thresholds.
- Five measurements of oxygen saturation including ≤ 89 and ≤ 88%.